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DNA Damage-Induced Phosphorylation of p53
Alleviates Inhibition by MDM2
phosphorylated at sites within its N-terminal and C-termi-
nal regions, and several protein kinases have been
shown to phosphorylate p53 in vitro. One such kinase
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identified is the double-stranded DNA-dependent pro-Columbia University
tein kinase, DNA-PK (Carter et al., 1990; Lees-Miller etNew York, New York 10027
al., 1990). Phosphorylation by DNA-PK is particularly² Ina Laboratories
interesting since both p53 and DNA-PK are crucial inMBL Co. Ltd.
maintaining the normality of the genome.Oohara Terasawaoka 1063-103
DNA-PK is a nuclear serine/threonine protein kinaseIna, Nagano 396
consisting of two components: a catalytic subunit (DNA-Japan
PKcs, p460) and a DNA-targeting partner called Ku au-³National Cancer Center Research Institute
toantigen (Carter et al., 1990; Lees-Miller et al., 1990).Tsukiji 5-chome
DNA-PKcs is a member of the PI-3 kinase family, andChuo-ku, Tokyo 104
its activity can be inhibited by the PI-3 kinase-specificJapan
inhibitor, wortmannin (Hartley et al., 1995). Activation of
DNA-PK requires DNA double-strand breaks or other
discontinuities in DNA(Gottlieb and Jackson, 1993; Mor-Summary
ozov et al., 1994). Owing to its peculiar characteristics,
the kinase has long been speculated to play a role inDNA-damaging agents signal to p53 through as yet
DNA repair. Indeed, cells lacking either component ofunidentified posttranscriptional mechanisms. Here we
DNA-PK were found to be defective in DNA double-show that phosphorylation of human p53 at serine
strand break repair and highly sensitive to ionizing radia-15 occurs after DNA damage and that this leads to
tion (Finnie et al., 1995; Lees-Miller et al., 1995). Cellsreduced interaction of p53 with its negative regulator,
defective in p460 or Ku are also unable to perform V(D)Jthe oncoprotein MDM2, in vivo and in vitro. Further-
recombination, the site-specific recombination eventmore, using purified DNA-dependent protein kinase
that takes place in developing B and T lymphocytes(DNA-PK), we demonstrate that phosphorylation of
(Blunt et al., 1995; Nussenzweig et al., 1996; Zhu et al.,p53 at serines 15 and 37 impairs the ability of MDM2
1996). Several mutant cell lines with dysfunctional DNA-to inhibit p53-dependent transactivation. We present
PK have been established. For example, the p460 cata-evidence that these effects are most likely due to a
lytic subunit was found to be diminished in murine scidconformational change induced upon phosphorylation
(for severe combined immunodeficiency) cells (Blunt etof p53. Our studies provide a plausible mechanism by
al., 1995; Kirchgessner et al., 1995) and absent in awhich the induction of p53 can be modulated by DNA-
human glioblastoma cell line M059J (Lees-Miller et al.,PK (or other protein kinases with similar specificity)
1995), while the Ku antigen was found to be absent inin response to DNA damage.
Chinese hamster xrs cells (Finnie et al., 1995). Despite
their close physiological link, there is no report thus farIntroduction
as to whether phosphorylation of p53 at its DNA-PK
sites is altered in cells after DNA damage.
Upon DNA damage, p53 protein accumulates rapidly
DNA-PK phosphorylates human p53 at serines 15 and
through a posttranscriptional mechanism(s) and is also
37, and murine p53 at serine 18 in vitro (Wang and
activated as a transcription factor, which then leads to Eckhart, 1992; Lees-Miller et al., 1992). Mutation of the
growth arrest or apoptosis (reviewed in Gottlieb and
serine 15 phosphorylation site in human p53 reduced
Oren, 1996; Ko and Prives, 1996; Levine, 1997). Accumu-
the growth suppression ability of p53 by about 50%
lation of p53 is absent or delayed in some types of cells
(Fiscella et al., 1993). The DNA-PK phosphorylation sites
defective in DNA repair (Kastan et al., 1992; Lu and Lane, are localized within the transcriptional activation domain
1993; Nelson and Kastan, 1994). At least in one case of p53, which interacts with certain polypeptides within
(ataxia-telangiectasia), overexpression of p53 was able the general transcription machinery, such as the TAFs
to restore growth arrest in the defective cells (Khanna (human TAF31 and TAF70 or Drosophila TAF42 and
et al., 1995). TAF62) (Lu and Levine, 1995; Thut et al., 1995), and
The mechanisms that govern the p53 damage re- cellular coactivators p300/CBP (Avantaggiati et al.,
sponse still remain elusive. Phosphorylation and de- 1997; Gu et al., 1997; Lill et al., 1997). These phosphory-
phosphorylation may be key regulatory steps, not only lation sites are also located in proximity to the region
because they have been shown repeatedly to mediate where p53 binds the product of the mdm2 oncogene
signal transduction from the cell surface to the nucleus (amino acids 18±23) (Kussie et al., 1996 and references
(reviewed in Karin and Hunter, 1995), but also because therein). MDM2 is an inhibitor of p53-mediated tran-
several studies have shown that phosphorylation of the scriptional activation (Momand et al., 1992; Oliner et
p53 protein can regulate its functions in vivo and in vitro al., 1993), while the mdm2 gene possesses two p53
(reviewed in Meek, 1994; Milczarek et al., 1997). p53 is response elements in its first intron and can be activated
by p53 (Juven et al., 1993; Wu et al., 1993). Thus, p53
increases MDM2 at the transcriptional level while MDM2§To whom correspondence should be addressed.
Cell
326
result led us to speculate that p53 may be posttransla-
tionally modified upon DNA damage such that its inter-
action with MDM2 is hindered.
As mentioned above, a good candidate for such modi-
fication is phosphorylation by DNA-PK. We purified
DNA-PK from HeLa cells and showed it to be heavily
dependent on the presence of DNA ends for its ability
to phosphorylate p53 (Figure 2A, lanes 1±3). Further-
more, the kinase activity was strongly reduced in the
presence of the PI-3 kinase-specific inhibitor wortman-
nin (see Figure 6B). DNA-PK was further tested on three
mutant p53 proteins, A15, A37, and A15A37, which have
Figure 1. Association of MDM2 with p53 Does Not Increase in Pro- either serine 15, serine 37, or both, replaced by alanine.
portion to the Levels of p53 and MDM2 after DNA Damage Significant reduction of phosphorylation of these p53
LNCaP cells were g-irradiated (7G), and cell extracts were prepared mutants was observed (Figure 2A). To investigate a pos-
at different time points following irradiation as indicated. One-tenth
sible involvement of DNA-PK (or phosphorylation atof each extract was used for Western blotting (upper panel), while
DNA-PK sites) in the p53-mediated damage response,the rest was used to immunoprecipitate p53 using PAb421 (lower
we utilized an antibody directed against an epitopepanel). The p53 andMDM2 proteins were detected using anti-MDM2
antibody SMP14 in combination with anti-P53 antibodies PAb421 spanning phospho±Ser-15 in p53 (ap53-P±Ser-15). The
and PAb1801 in the Western blot (upper panel) or the MDM2 anti- antibody reacted strongly with DNA-PK-phosphorylated
body SMP14 following immunoprecipitation (lower panel). wild-type p53 as well as A37 mutant p53 (Figure 2B,
lanes 1±3 and lanes 7±9), but not with the A15 and
A15A37 mutants regardless of DNA-PK treatment (Fig-
suppresses p53 activity at the posttranslational level. ure 2B, lanes 4±6 and lanes 10±12), demonstrating the
This creates an autoregulatory feedback loop in which specificity of the antibody.
both the activity of p53 and the expression of MDM2 The ap53-P±Ser-15 antibody was subsequently used
are coregulated. The importance of the MDM2±p53 in- to examine the phosphorylation status of p53 in cells.
teraction was further supported by studies that showed As shown in Figure 2C, this antibody recognized p53
that deletion of p53 alleles rescued the embryonic lethal isolated from LNCaP cells that had been treated with
phenotype of mdm2-null mice (de Oca Luna et al., 1995; ionizing radiation (lanes 2±6, upper panel). The kinetics
Jones et al., 1995). Interestingly, MDM2 was recently of induction with respect to phosphorylation coincided
reported to regulate p53 stability in cells (Haupt et al., with or were slightly earlier than the accumulation of
1997; Kubbutat et al., 1997). Since the DNA-PK sites are p53 (lower panel). As a further control, the ap53-P±Ser-
located in the vicinity of the MDM2 interaction motif, it 15 antibody did not recognize alkaline phosphatase-
was therefore of great interest to determine how phos- treated, purified p53 (Figure 2C, lane 7, upper panel),
phorylation of p53 affects its interaction with MDM2 and but reacted strongly with p53, which had been phos-
the consequences of any effects noted. phorylated in vitro with purified DNA-PK (lane 8, upper
panel), despite that both lanes contain similar amounts
Results of p53 (Figure 2C, lanes 7 and 8, lower panel). p53 was
also recognized by the ap53-P±Ser-15 antibody after
DNA Damage Induces Phosphorylation irradiation of cells from the human RKO cell line (Figure
of p53 at Serine 15 2D) and the murine fibroblast cell line CB17 (data not
We first examined the kinetics of induction of p53 and shown), demonstrating that such induction is not unique
MDM2 following DNA damage. As shown in Figure 1, to one particular cell line. In addition to ionizing radia-
p53 was rapidly induced within 30 min after treatment tion, serine 15 phosphorylation was also induced by
with g irradiation in LNCaP cells, a human prostrate other DNA damaging agents such as camptothecin
adenocarcinoma cell line with wild-type p53 (Nelson and and UV irradiation (Figure 2E). Thus, p53 induced by a
Kastan, 1994). The level of p53 peaked at 2 hr and then variety of DNA damage treatments is phosphorylated at
returned to near basal level after 4 hr. Increased MDM2 serine 15.
was first noted at 1 hr postirradiation and continued While the above experiments suggest a DNA damage-
to accumulate at 4 hr, confirming the MDM2 induction induced phosphorylation of p53, they did not address
kinetics reported by Haupt et al. (1997) and supporting the issue as to whether p53 is constitutively phosphory-
the likelihood that MDM2 was induced in response to lated in normal, unirradiated cells. It is possible that the
p53. The same sets of extracts were also used in coim- failure to detect phosphorylation of p53 prepared from
munoprecipitation assays in which p53/MDM2 com- untreated cells was because of the low level of p53 in
plexes were brought down by the p53 antibody PAb421. these cells and the limitation of the sensitivity of the
The amount of MDM2 in the immunoprecipitates was antibody. To exclude this possibility, we sought to stabi-
then determined by Western blotting using the MDM2 lize p53 by using the calpain/proteasome inhibitor LLnL
monoclonal antibody SMP14 (Picksley et al., 1994). In- (Maki et al. 1996). Under this condition, while p53 was
terestingly, although the levels of p53 and MDM2 in- greatly stabilized (indeed, to a similar level as seen after
creased during the course of damage response, the DNA damage) (Figures 3A and 3B, compare lanes 1 and
amount of MDM2 in complex with p53, and therefore 2), it was not recognized by ap53-P±Ser-15 (Figure 3B,
brought down by p53 antibody, remained fairly constant lane 2). By contrast, again, a similar level of p53 induced
after g irradiation was clearly recognized by ap53-P±throughout the time course (Figure 1, lanes 1±5). This
p53 Phosphorylation Modulates Inhibition by MDM2
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Figure 2. Phosphorylation of p53 at Serine 15 Is Induced by DNA Damage
(A and B) Mutation at serines 15 and/or 37 severely diminishes phosphorylation of p53 by DNA-PK (A). In vitro assays of DNA-PK in the
presence or absence of DNA as indicated were performed using immunopurified wild-type or mutant p53 proteins, A15, A37, and A15A37.
One-fourth of each reaction mixture was resolved on a 10% SDS gel. The wet gel was first subjected to autoradiography for 30 min (upper
panel), then transferred to nitrocellulose for Western blotting using PAb421 and Pab1801 (lower panel). The levels of phosphorylation were
measured using a PhosphorImager (Molecular Dynamics), and the results are shown in the bar graph below. (B) The ap53-P±Ser-15 antibody
recognizes specifically p53 phosphorylated at serine 15. Kinase assays and SDS-PAGE were carried out as described in (A) and transferred
to nitrocellulose membrane. The membrane was first probed with ap53-P±Ser-15 (PS15) (top panel), stripped, and then reprobed with a
mixture of p53-specific antibodies PAb1801 and PAb421 (lower panel).
(C) Phosphorylation of human p53 at serine 15 is detected after ionizing radiation. p53 immunoprecipitated from LNCaP cell extracts described
in the legend of Figure 1 was first probed with ap53-P±Ser-15 (PS15), then stripped and reprobed with p53 antibody PAb421 and PAb1801.
Purified p53 proteins treated with alkaline phosphatase (lane 7) or phosphorylated with purified DNA-PK in vitro (lane 8) were run on the same
gel.
(D) g irradiation induces phosphorylation of p53 in RKO cells. Cell extracts were prepared 2 hr after irradiation and assayed as described in
the legend to Figure 1.
(E) Phosphorylation at serine 15 is induced by camptothecin (CPT) and UV irradiation. LNCaP cells were treated either with g irradiation (7G)
and harvested 2 hr later, or 0.25 mM CPT for 3 hr, or 50 JM-2 of UV and harvested after 16 hr. Cell extracts were then assayed as described
above.
Ser-15 (Figure 3B, lane 3). This is not due to inhibition in negatively regulating the interaction between p53 and
MDM2, and possibly the activity of p53. Indeed, by prob-of phosphorylation by LLnL, since g irradiation in the
presence of LLnL induced phosphorylation at serine 15 ing the same extracts with p21/WAF antibody, we found
significantly more p21/WAF expressed in g-irradiatedto a similar degree as did treatment with g irradiation
alone (Figure 3B, lane 4). Similar observations were than in LLnL-treated LNCaP cells (data not shown). We
also detected relatively greater amounts of MDM2 asso-made in RKO cells (Figures 3C and 3D). Taken together,
these results demonstrate that the reactivity with ap53- ciated with LLnL-stabilized p53 than with g irradiation±
induced p53 in RKO cells (Figures 3C and 3D). Collec-P±Ser-15 represents a de novo induction of phosphory-
lation by g irradiation. tively, our results provide a striking correlation between
the acquisition of phosphate at serine 15 on p53 in re-
sponse to DNA damage, a reduction in the amount ofPhosphorylation at the p53 DNA-PK Sites Is
Incompatible with the p53±MDM2 Interaction MDM2 associated with p53, and a concomitant increase
in the transcriptional activity of p53.In addition to a disproportionate coprecipitation of
MDM2 with DNA damage-induced p53 (Figure 1), we
also observed that relatively more MDM2 was associ- Phosphorylation of p53 by DNA-PK Attenuates
the Interaction of p53 with MDM2 In Vitroated with LLnL-induced p53 than with p53 induced by
g irradiation in LNCaP cells (Figure 3B, compare lanes To examine directly the effect of phosphorylation at
DNA-PK sites on the interaction of p53 with MDM2, we2 and 3), even though somewhat less MDM2 was found
in LLnL-treated extracts than in g-induced extracts (Fig- employed in vitro coimmunoprecipitation assays. [35S]-
labeled murine MDM2 was translated in vitro, and in-ure 3A, lanes 2±4). This suggests that DNA damage-
induced phosphorylation at serine 15 may be involved cubated with purified full-length unphosphorylated or
Cell
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Figure 3. Ionizing Radiation Induces Phosphorylation of p53 at Ser-
ine 15 and Leads to Reduced p53-MDM2 Interaction
(A and B) Cell extracts (one-tenth) isolated from LNCaP cells treated
with 50 mM LLnL for 2 hr, or 3 hr after 7Gy of g irradiation, or from
cells treated with both LLnL and g, were analyzed by SDS-PAGE
and transferred to nitrocellulose (A). The blot was first probed with
p53 and MDM2 antibodies (PAb421, PAb1801, SMP14), stripped,
then reprobed with anti-b-actin antiserum. (B) p53 in nine-tenths of
cell extracts left from (A) was immunoprecipitated with PAb421 and
detected by Western blotting. The membrane was probed first with
Figure 4. Phosphorylation of p53 by DNA-PK at Serine 15 and Ser-ap53-P±Ser-15 (PS15), then stripped and reprobed with PAb421
ine 37 Inhibits Interaction with MDM2 In Vitroand PAb1801. The MDM2 protein in these immunoprecipitates was
detected using the monoclonal antibody SMP14. (A) Impaired interaction of p53 with murine MDM2 upon DNA-PK
(C) and (D) are the same as in (A) and (B), respectively, except that phosphorylation. Coimmunoprecipitation experiments were per-
experiments were conducted using extracts of RKO cells. formed with 3 ml of in vitro synthesized, [35S]-labeled murine MDM2
and 200 ng of either DNA-PK-phosphorylated (lane 4) or unphos-
phorylated p53 (lane 3). The complex was then brought down by
p53 antibody PAb421 followed by SDS-PAGE. The amount of MDM2
DNA-PK-phosphorylated human p53 protein followed in the immunoprecipitates was detected by autoradiography. Lane
by immunoprecipitation with the p53-specific antibody 1, 10% of input. The results were quantified using a densitometer
PAb421. While murine MDM2 bound p53 (Figure 4A, (Bio Image, Millipore) and depicted in the accompanying bar graph.
I.O.D., integrated optical density, shown as arbitrary units.lane 3), this interaction was markedly reduced (by 70%)
(B) Phosphorylation at the p53 DNA-PK sites leads to reduced inter-upon phosphorylation of p53 by DNA-PK (Figure 4A,
action with human MDM2. Human MDM2 (HDM) was immunoprecip-lane 4) as quantified by densitometer measurement (Fig-
itated from HDM baculovirus-infected Sf9 cell extracts using SMP14
ure 4A, right panel). Coimmunoprecipitation experi- antibody. The immunoprecipitates were washed and then incubated
ments were also conducted to examine the effect of with 200 ng of either unphosphorylated or DNA-PK-phosphorylated
DNA-PK phosphorylation on the interaction of human wild-type or mutant p53 as indicated. p53 proteins in the immuno-
precipitates were detected by Western blotting using PAb240 andMDM2 (HDM) with p53. Here the full-length HDM protein
PAb1801 (upper panel). The membrane was stripped and reprobedexpressed in Sf9 cell extracts was first immunoprecipi-
with SMP14 to detect HDM (middle panel). The bar graph (lowertated with the MDM2-specific antibody, washed, and
panel) depicts the relative amounts of p53 in SMP14 immunoprecipi-
then incubated with purified p53 (DNA-PK-phosphory- tates as quantified by densitometer measurement.
lated or unphosphorylated). As seen with murine MDM2,
the interaction between HDM and p53 was reduced by
z75% following phosphorylation by DNA-PK (Figure 4B, MDM2 Down-Regulation of p53 Transactivation In
Vitro Is Alleviated by DNA-PK Phosphorylationlanes 2 and 3). Furthermore, in contrast to what we
observed with wild-type p53, there was no reduction in A question emerging from the above studies was
whether the observed interference by DNA-PK phos-the interaction with the double mutant A15A37 (Figure
4B, lanes 4 and 5). The effects of the single mutations phorylation on MDM2 interaction would affect MDM2-
mediated down-regulation of transactivation by p53. Toin p53 (A15 or A37) were intermediate such that in each
case there was approximately 50% reduction following address this, His-tagged full-length HDM protein and a
truncated HDM with theamino-terminal 165 amino acidsDNA-PK phosphorylation (lanes 6±9). Taken together,
these results demonstrate that phosphorylation of p53 deleted (dl166) was first expressed in and purified from
E. coli. We confirmed the results of Chen et al. (1993)at serines 15 and 37 strongly disfavors its interaction
with MDM2. that full-length but not dl166 recombinant HDM was able
p53 Phosphorylation Modulates Inhibition by MDM2
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Figure 5. Phosphorylation by DNA-PK Alle-
viates MDM2-Mediated Inhibition of p53-
Dependent Transactivation In Vitro
In vitro transcription was performed using
G-less cassette DNA templates carrying ei-
ther a p53 binding site derived from the WAF/
p21 gene promoter (WAFMLT) or five Gal4
binding sites linked to the adenovirus major
late minimal promoter (G5MLT), in the pres-
ence or absence of 20 ng purified p53 or 30
ng Gal4-VP16, respectively. p53* denotes
p53 that was prephosphorylated by DNA-PK.
AdMLT indicates transcripts derived from a
control template carrying 400 bp from the ad-
enovirus major late promoter. Amount of
HDMs used in the assay: full-length (fl), 150
ng; dl166 (dl), 190 ng. Both HDM proteins were also tested for their effects on transactivation by Gal4-VP16 (lanes 8±11). Fold activation over
basal transcription was determined by PhosphorImager analysis of WAFMLT or G5MLT transcripts.
to bind p53 in vitro (data not shown). The full-length Consistent with the above data, during experiments
examining the effects of DNA-PK phosphorylation onHDM protein was able to markedly inhibit p53-mediated
p53 sequence-specific binding, we observed an unusualtransactivation in vitro (WAFMLT), whereas the dl166
change in p53±DNA complexes after p53 was phosphor-mutant had no effect (Figure 5, lanes 1±4). The inhibition
ylated by this kinase (Figure 6B). p53 expressed in andwas specific, since MDM2 did not affect transactivation
purified from insect cells was prephosphorylated in vitromediated by Gal4-VP16 (G5MLT) (lanes 8±11), nor did
and subsequently tested in electrophoresis mobilityit have any effect on transcription from the reference
shift assays (EMSA) for its binding to an oligonucleotidetemplate containing the adenovirus major late promoter
containing the consensus site in the p21/WAF gene pro-(AdMLT) (lanes 1±4).
moter. Contrary to results obtained when p53 is phos-To examine the effect of DNA-PK, p53 was treated
phorylated at its C terminus (Hupp et al., 1992; Huppwith the kinase and then used in the transcription
and Lane, 1994; Takenaka et al., 1995; Wang and Prives,assays. Although the overall transactivation by p53 was
1995), phosphorylation by DNA-PK did not stimulatenot significantly altered, inhibition by MDM2 was allevi-
DNA binding by p53 in gel mobility shift assays (EMSA)ated by phosphorylation of p53 (Figure 5, lanes 5±7).
(Figure 6B, lower panel). However, p53±DNA complexesAdditionally, the double mutant A15A37 was equally ca-
displayed altered (and more rapid) electrophoretic mo-pable of responding to MDM2 inhibition with or without
bility after phosphorylation by DNA-PK (lane 2). The ab-DNA-PK pretreatment (data not shown). Thus, phos-
errant migration did not occur when phosphorylationphorylation of p53 by DNA-PK not only interferes with
was carried out in the presence of wortmannin (Figurethe binding of MDM2 to p53, but also confers resistance
6B, lower panel), indicating that the altered mobility istoward MDM2 down-regulation of p53 transactivation
indeed caused by DNA-PK phosphorylation.function. Our results additionally imply that phosphory-
To identify the serine residue that contributed to thelation at serines 15 and 37 provides a potential mecha-
observed altered mobility upon phosphorylation, thenism by which the inhibitory effect of MDM2 can be
DNA-binding activity of the A15, A37, and A15A37 mu-regulated.
tants was also examined by EMSA following phosphory-
lation. After treatment with DNA-PK, the double mutant,
Phosphorylation at the DNA-PK Sites Alters A15A37, failed to show any change in mobility, and the
the Tertiary Structure of p53 single mutants A15 and A37 displayed only intermediate
We employed partial proteolysis to test the possibility shifts in mobility of the complex (Figure 6B, right panel).
that the tertiary structure of p53 might be somehow These results show that the changed mobility observed
altered upon phosphorylation. The calcium-dependent following phosphorylation by DNA-PK is attributable to
protease calpain has recently been used successfully phosphorylation at serines 15 and 37. This is the first
to distinguish differences in conformations of wild-type example that demonstrateschanges in mobility of phos-
and mutant forms of murine p53 (Pariat et al., 1997). phorylated p53±DNA binding complexes. In conjunction
Using a similar approach, we observed a striking differ- with results of limited calpain digestion, our observa-
ence in calpain cleavage products derived from DNA- tions support a model in which phosphorylation at ser-
PK-phosphorylated and unphosphorylated p53 protein ines 15 and 37 alters the tertiary structure of p53. This
(Figure 6A). Limited cleavage of unphosphorylated p53 structural alteration may be responsible for the inhibition
yielded two major polypeptides of approximately 40 and of MDM2 binding by p53.
36 kDa (Figure 6A, lanes 1±4), whereas cleavage of the
DNA-PK-phosphorylated p53 gave rise to predomi- Discussion
nantly the 40 kDa polypeptide with only a trace amount
of the 36kDa product (lanes 6±9). Theeffect was attribut- Phosphorylation at Serines 15 and 37 Interferes
able to phosphorylation at serines 15 and 37, since mu- with MDM2 Interaction and Alleviates
tation of these serines to alanines completely abolished MDM2-Mediated Inhibition
the difference in calpain susceptibility with respect to Using coimmunoprecipitation assays, we demonstrated
that phosphorylation by DNA-PK of p53 at serines 15DNA-PK treatment (lanes 10±18).
Cell
330
Figure 7. A Model Depicting a Potential Mechanismby which MDM2
Inhibition Can Be Modulated by DNA Damage-Induced Phosphory-
lation of p53
Under normal unstressed conditions, p53 associates with its inhibi-
tor MDM2, and p53-dependent transactivation is repressed. Upon
genotoxic assaults, such as ionizing irradiation, p53 is phosphory-
lated at serine 15, which in turn induces a conformational change
in p53. MDM2 is unable to bind p53 in the latter conformation, and
transcriptional inhibition by MDM2 is relieved.
such as the moment following DNA damage. Our results
Figure 6. Conformational Change in p53 after DNA-PK Phosphory- are consistent with a model (Figure 7) that one of the
lation
functions of phosphorylation at these N-terminal sites
(A) Altered calpain cleavage of phosphorylated versus unphosphor-
may be to deter the inhibitory effect of MDM2 in theylated p53. Cleavage of either wild-type or A15A37 mutant p53 was
early phase of the p53 response, so that p53 can remaincarried out with calpain in the presence of 1 mM CaCl2 at 378C for
active when it is needed most. In the later phase whenthe indicated time and then stopped by addition of SDS loading
buffer followed by boiling for 5 min. Minus and plus signs indicate MDM2 has been induced by p53, the p53-MDM2 auto-
the absence and the presence of DNA-PK, respectively, in kinase regulatory loop proposed by Wu et al. (1993) may come
reactions. EGTA (1 mM) was added to reaction mixtures run in lanes into play and turn off the p53 response, so that cell cycle
5 and 14 to confirm the calcium dependency of the protease.
can resume. Although the validity of the model remains(B) Phosphorylation of p53 by DNA-PK results in the altered mobility
tobe tested in cells, it provides a possible mechanism byof p53±DNA complexes. (Left panel) kinase assays were conducted
which the inhibitory effect of MDM2 can be modulatedwith or without DNA-PK, DNA, or wortmannin (0.5 mM) as indicated,
followed by SDS-PAGE. The wet gel was subjected to autoradiogra- through phosphorylation induced upon DNA damage.
phy (kinase assay), then transferred to nitrocellulose and probed In addition, in light of the recent observations by Haupt
with p53 antibodies PAb240 and PAb421 (Western blot). p53 treated et al. (1997) and Kubbutat et al. (1997) that MDM2 targets
as in lanes 2±4 (top) was also tested in the gel mobility assay and
p53 for degradation, we propose that such phosphoryla-the results are shown at bottom (lanes 1±3). The upper arrow indi-
tion may be responsible for the characteristic stabiliza-cates the slower migrating (unphosphorylated) and the lower arrow
tion of p53 protein after DNA damage.indicates the faster migrating (phosphorylated) forms of the p53±
DNA complexes. (Right panel) kinase reactions and gel mobility- It is intriguing how phosphorylation at these sites af-
shift assays were conducted as described above using wild-type fects MDM2 interaction. The crystal structure of an
(WT) or mutant p53 proteins treated with DNA-PK alone (minus) or N-terminal domain of Xenopus MDM2 (residue 13±118)
DNA-PK plus DNA (plus) in the kinase reactions. Pi denotes the
binding to a peptide derived from human p53 (residuescondition that gives rise to phosphorylation (DNA-PK 1 DNA).
13±29) revealed that MDM2 binds to p53 via a hydropho-
bic cleft, and several hydrophobic residues in the N
terminus of p53 are critical for the interaction (Kussieand 37 hinders its interaction with MDM2. Such interfer-
ence was also reflected in MDM2 down-regulation of et al., 1996). Similar conclusions were reached by BoÈ tt-
ger et al. (1996) using a phage library screening ap-p53 transcriptional activity; upon phosphorylation, p53
became more resistant to inhibition by MDM2 (Figure proach. Assuming that human MDM2, which shares 71%
identity to Xenopus MDM2, binds p53 through a similar5). In accordance with this finding obtained with purified
materials in vitro, we also observed a decreased level mode, it is quite possible that charged phosphate
groups may alter the overall hydrophobicity in the vicin-of MDM2 in complexes with p53 when serine 15 was
phosphorylated in vivo (Figure 3). It is tempting to specu- ity of the interacting motif, thus making MDM2 interac-
tion unfavorable. However, charge may not be the onlylate that cells possess mechanisms to modulate MDM2-
mediated inhibition at a time when cells need p53 most, factor, since mutation of serine 15 to aspartic acid did
p53 Phosphorylation Modulates Inhibition by MDM2
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not prevent overexpressed p53 from being targeted by 15 (S. Y. S., Y. T., and C. P., unpublished data). On the
basis of these results, two scenarios can be envisioned.MDM2 for degradation (Kubbutat et al., 1997). The other
In the first scenario, phosphorylation of the serine 15possible mechanism, as suggested by our studies, is
residue is indeed carried out by DNA-PK in scid cells,alteration in the tertiary structure of p53 protein. Our
but to a lesser extent when compared to normal cells.results, that phosphorylation at the DNA-PK sites results
The scid mutation has recently been characterized andin alteration of not only the calpain digestion pattern
shown to be a C-terminal truncation, which results inbut also the mobility of p53±DNA complexes (Figure 6),
a much more unstable protein (Danska et al., 1996).support the probability that there is a significant change
However, the scid mutation leaves the PI-3 kinase con-in p53 conformation induced by phosphorylation at ser-
sensus motifs intact, and the mutant DNA-PK can stillines 15 and 37. Although it is also possible that the
theoretically perform its kinase function, however imper-increased negative charge resulting from DNA-PK phos-
fectly. In the second scenario, p53 is phosphorylatedphorylation enhanced p53 mobility in native gels, we
by a kinase other than DNA-PK that possesses similarconsider that unlikely, since the mobility of p53±DNA
substrate specificity. Indeed, DNA-PK is not the onlycomplexes is not changed following CK II, PK C (Hupp
kinase that has a PI-3 kinase homology domain in cellset al., 1992; Hupp and Lane et al., 1994; Takenaka et al.,
(Keith and Schreiber, 1995). For example, ATM, another1995) or cdk (Wang and Prives, 1995) phosphorylation.
member of the nuclear PI-3 kinase family, was found toSince the N-terminal region of p53 binds TAFs as well
be mutated in ataxia telangiectasia (AT) patients whoas MDM2, a question emerging is whether phosphoryla-
are highly sensitive to ionizing radiation (Savitsky et al.,tion of p53 also affects its interaction with TAFs. The
1995) and, like p53, is involved in regulating genomeL22Q/W23S mutation disrupts the ability of p53 to inter-
stability (reviewed in Hawley and Friend, 1996). How-act with both TAFs (Thut et al., 1995) and MDM2 (Lin et
ever, since the p53 response to UV irradiation is normalal., 1994), suggesting that these proteinsbind toa similar
in AT cells (Lu and Lane, 1993; Canman et al, 1994;or overlapping region on p53. However, while phosphor-
Khanna et al. 1995), our data that serine 15 phosphoryla-ylation at serines 15 and 37 inhibited MDM2 binding
tion is induced by UV suggest that ATM might not be
(Figure 4), the ability of p53 to function as a transcrip-
the protein kinase that directly phosphorylates p53 in
tional activator was not affected in vitro (Figure 5). It is
vivo. Assuming that structural homology represents
possible that the nature of the interaction(s) between
functional similarity, we can speculate that other mem-
p53 and TAFs is different from that between p53 and ber(s) of the PI-3 kinase family may have similar sub-
MDM2, or the motifs in p53 required for binding TAFs strate specificity and can phosphorylate p53 at the same
and MDM2 are not overlapping. A detailed structure± sites as does DNA-PK. It would be interesting to see if
function analysis would be required to give a definitive any of these kinases can indeed phosphorylate p53 and
answer. if such phosphorylation affects the MDM2-p53 interac-
tion as described in this report.
Physiological Role of DNA-PK in the DNA Experimental Procedures
Damage Response
Several lines of evidence indicate that DNA-PK may be Cell Culture and Preparation of Cell Lysates
LNCaP cells (human prostate adenocarcinoma cells, ATCC) andan important player in the genotoxic stress response.
RKO cells (human colorectal carcinoma cells, kindly provided by M.First, the activity of DNA-PK requires the presence of
Kastan) were maintained in RPMI and DMEM, respectively, with 10%abnormal DNA structures such as nicks, gaps, double- fetal bovine serum. Cells were treated with the calpain/proteasome
strand breaks (DSBs), and hairpin loops (Gottlieb and inhibitor N-acetyl-Leu-Leu-norleucinal (LLnL) (Sigma) or g-irradiated
Jackson, 1993; Morozov et al., 1994), which are gener- in their exponential growing phase. Cell extractswere then prepared
by lysing the cells in buffer containing 10 mM Tris (pH 7.5), 1 mMated by DNA damage agents or by repair process. Sec-
EDTA, 400 mM NaCl, 10% glycerol, 0.5% NP40, 5 mM NaF, 0.5ond, inactivation of the kinase activity by mutating the
mM sodium orthovanadate, 1 mM dithiothreitol (DTT), and 0.1 mMcatalytic subunit or the Ku subunits impairs DSB repair
phenylmethylsulfonyl fluoride (PMSF). Lysates were incubated on
and V-D-J recombination (Blunt et al., 1995; Peterson ice for 15 min and spun for 10 min in microcentrifuge to remove cell
et al., 1995; Nussenzweig et al., 1996; Zhu et al., 1996). debris. For immunoprecipitation, cell lysates were mixed with an
equal volume of TEG buffer (10 mM Tris [pH 7.5], 1 mM EDTA, 20%Third, we and others have presented substantial evi-
glycerol, 5 mM NaF, 0.5 mM sodium orthovanadate, 1 mM DTT, 0.1dence that DNA-PK phosphorylates the p53 protein in
mM PMSF) and PAb421-protein A Sepharose beads and rocked atthe presence of DNA ends and, as suggested in this
48C for 2 hr. The immunoprecipitates were then washed four times
report, this modification provides a possible mechanism with 10S buffer (50 mM HEPES (pH 7.9), 250 mM KCl, 0.2% NP40,
by which the interaction between MDM2 and p53 can 0.1% Triton X-100, 0.01% SDS, 1 mM DTT), resuspended in 33 SDS
gel-loading buffer (0.5 M Tris [pH 6.8], 2 M b-mercaptoethanol, 12%be modulated in response to DNA damage.
SDS, 30% glycerol, 0.1% bromophenol blue), and analyzed on 10%Despite the potential link between p53 and DNA-PK,
SDS-polyacrylamide gels.their relationship was cast into serious doubt after sev-
eral studies showed that the p53 response and the G1 Generation of ap53-P±Ser-15 Antibody
cell cycle arrest was normal in DNA-PKcs-defective scid The phospho-Ser-15±specific antiserum was raised against a
cells (Fried et al., 1996; Guidos et al., 1996; Gurley and chemically synthesized, KLH-conjugated phosphopeptide SVEPPLS
(PO3)QETFSDC (amino acids 9±21) as previously described (Kita-Kemp, 1996; Huang et al., 1996; Rathmell et al., 1997).
gawa et al., 1996). The antiserum was further affinity purified throughImportantly, however, using the antibody that recog-
a phosphopeptide-conjugated Sepharose CL-4B column. To de-
nizes specifically p53 phosphorylated at serine 15 (ap53- plete antibodies that recognize unphosphorylated p53, the affinity-
P±Ser-15), we have found that in murine scid cells the purified ap53-P±Ser-15 was then passed through a column conju-
gated with unphosphorylated peptide SVEPPLSQETFSD. Whenp53 protein is constitutively phosphorylated at serine
Cell
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used in Western analyses, the antibody was preincubated with the were then detected by Western blot analysis using a mixture of p53
antibodies (PAb240 and PAb1801) or MDM2 antibody SMP14.unphosphorylated peptide to block any residual reactivity with un-
phosphorylated p53.
In Vitro Transcription
Partial Purification of DNA-PK In vitro transcription reactions were carried out essentially as de-
DNA-PK was partially purified from HeLa nuclear extracts as de- scribed previously (Farmer et al., 1992) but using 50 ng of G-less
scribed by Lees-Miller et al. (1990) by using two consecutive chro- DNA templates. Proteins and DNA were preincubated at room tem-
matographic columns. Nuclear extracts were prepared from 6 l of perature for 10 min before nucleotides were added to the mixture.
HeLa cell culture (6 3 105 cells/ml). The crude extract was first Reaction mixtures (20 ml) contained 2.5 mM NaF, 0.5 mM orthovana-
passed through a DEAE-Sephacel column (Pharmacia). The bound date, 10 mM HEPES (pH 7.9), 12 mM Tris (pH 8.0), 0.1 mM EDTA,
fraction was eluted with HEPES buffer (25 mM N-2-hydroxyethylpi- 12% glycerol, 60 mM KCl, 5 mM MgCl2, 0.5 mM ATP, 0.5 mM UTP,
perazine-N-2-ethanesulfonic acid [HEPES] [pH 7.8], 0.2 mM EDTA, 20 mM CTP, 0.25 mM O-methyl-GTP, 5 mM creatine phosphate, 5
0.5 mM DTT, 0.5 mM PMSF) containing 0.5 M KCl and further purified mCi [a-32P] CTP, and 50 U RNase T1 (BRL). The DNA template
through a dsDNA-cellulose (Sigma) column. The DNA-PK activity pG5MLT contains five Gal4 binding sites linked to the adenovirus
was eluted between 0.2 M and 0.4 M KCl, dialyzed into HEPES major late basal promoter (250±110) and a G-less cassette. The
buffer containing 0.1 M KCl and 20% glycerol, and stored at 2708. template pWAFMLT was generated by replacing the Gal4 sites with
a p53-binding oligonucleotide derived from the p21/WAF gene pro-
In Vitro Kinase Assays moter. Both templates gave rise to transcripts of 390 nucleotides,
Kinase assays were conducted in 20 ml reactions in Z9 0.05 buffer which were detected by 4% urea-acrylamide gel electrophoresis
(25 mM HEPES [pH 7.9], 50 mM KCl, 10 mM MgCl2, 20% glycerol, followed by autoradiography. A control template, AdMLT, was in-
1 mM DTT) containing 0.5 ml of partially purified DNA-PK, 15 mCi of cluded in some experiments, which gives rise to transcripts of 190
[g-32P]ATP, 8 mM ATP, 150±200 ng of baculovirus-expressed, puri- nucleotides.
fied p53, and 10 mg/ml of DNA fragments generated from HpaII
digested pBluescript. The mixtures were incubated at 308C for 15 Calpain Cleavage
min. One fourth of the reaction mixture was then separated on a Kinase reactions were set up with purified wild-type or A15A37
10% SDS-polyacrylamide gel, and the signals were subsequently mutant p53 proteins (200 ng) in the presence or absence of DNA-
detected by autoradiography on the wet gel. To ensure equal PK. After 15 min incubation at 308C, wortmannin (0.5 mM) was added
amounts of protein input, the same gel used for autoradiography to stop the reaction. Following normalizing the amount of DNA-PK
was subsequently transferred to nitrocellulose, and p53 was de- in each tube, one-twentieth of each reaction mixture (10 ng) was
tected using a mixture of p53 antibodies PAb421 and PAb1801. then used for cleavage with calpain, which was carried out in PBS
The proteins were visualized using enhanced chemiluminescence containing 1 mM CaCl2 and 0.03 U of calpain (mCANP, Sigma) at
reagents (ECL, Amersham). In experiments where alkaline phospha- 378C for the indicated time. The cleavage was stopped by adding
tase was used, 4 units of phosphatase (Boehringer Mannheim, 20 SDS gel-loading buffer, and the mixture was boiled and analyzed
u/ml) were added to the kinase reaction mixture and incubated at on a 10% SDS-PAGE gel.
308C for 15 min to dephosphorylate p53.
Gel Mobility-Shift Assays
Generation and Preparation of p53 DNA-PK DNA binding assays were conducted in 20 ml Z9 0.05 buffer on ice
Site Mutants for 30 min in the presence of 200 ng of p53 and 0.1 ng of a [32P]-
The cDNA encoding the A15A37 double mutant was generated by labeled oligonucleotide containing the p53 consensus site in the
swapping part of the A15 and A37 cDNAs (Fiscella et al., 1993) using p21/WAF gene promoter (59-AATTCTCGAGGAACATGTCCCAACAT
the unique Psp1406 I site. Wild-type and mutant cDNAs were cloned GTTGCTCGAGAATT-39). Reaction mixtures were then analyzed on
into pBacPAK8 vector (Clontech) and used to produce baculovi- 4% native acrylamide gels in 0.53 TBE, and gels were dried and
ruses in Sf9 cells. All p53 proteins used in this study were immuno- subjected to autoradiography. To assess the effect of phosphoryla-
purified through PAb421 columns and eluted with a peptide span- tion on the mobility of the p53±DNA complexes, purified p53 was
ning the PAb421 epitope. first treated with DNA-PK under phosphorylation (plus DNA) or non-
phosphorylation (minus DNA) conditions at 308C for 15 min and then
Expression of Recombinant HDM used in the binding reactions after normalizing the amount of DNA.
To generate recombinant human MDM2 (HDM) protein, a near full-
length human mdm2 cDNA encoding amino acids 5±497 (fl) and a
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